CN101925611A - Wise结合剂和表位 - Google Patents

Wise结合剂和表位 Download PDF

Info

Publication number
CN101925611A
CN101925611A CN2008801252375A CN200880125237A CN101925611A CN 101925611 A CN101925611 A CN 101925611A CN 2008801252375 A CN2008801252375 A CN 2008801252375A CN 200880125237 A CN200880125237 A CN 200880125237A CN 101925611 A CN101925611 A CN 101925611A
Authority
CN
China
Prior art keywords
seq
cdr sequences
cdr
wise
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2008801252375A
Other languages
English (en)
Chinese (zh)
Inventor
X·钱
K·格雷厄姆
G·施马莫托
B·S·蒂普顿
M-M·蔡
A·G·温特斯
L·张
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CN101925611A publication Critical patent/CN101925611A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN2008801252375A 2007-11-21 2008-11-21 Wise结合剂和表位 Pending CN101925611A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US403707P 2007-11-21 2007-11-21
US61/004037 2007-11-21
PCT/US2008/012987 WO2009070243A2 (en) 2007-11-21 2008-11-21 Wise binding agents and epitopes

Publications (1)

Publication Number Publication Date
CN101925611A true CN101925611A (zh) 2010-12-22

Family

ID=40524859

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2008801252375A Pending CN101925611A (zh) 2007-11-21 2008-11-21 Wise结合剂和表位

Country Status (17)

Country Link
US (2) US8043620B2 (enExample)
EP (1) EP2220118A2 (enExample)
JP (2) JP5583591B2 (enExample)
KR (1) KR20100099193A (enExample)
CN (1) CN101925611A (enExample)
AU (1) AU2008330125B2 (enExample)
BR (1) BRPI0820387A2 (enExample)
CA (1) CA2705879A1 (enExample)
CO (1) CO6311002A2 (enExample)
CR (1) CR11523A (enExample)
EA (1) EA201000844A1 (enExample)
IL (1) IL205569A0 (enExample)
MA (1) MA31918B1 (enExample)
MX (1) MX2010005656A (enExample)
TN (1) TN2010000213A1 (enExample)
WO (1) WO2009070243A2 (enExample)
ZA (1) ZA201003578B (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112180099A (zh) * 2020-09-15 2021-01-05 江南大学附属医院 子宫内膜异位症血清标志物的应用
CN114364694A (zh) * 2019-07-12 2022-04-15 国立大学法人京都大学 靶向usag-1分子的用于牙齿再生治疗的中和抗体
CN116712533A (zh) * 2023-07-03 2023-09-08 广东暨安特博生物科技有限公司 一种sostdc1蛋白在制备治疗皮肤病产品中的应用
CN115322258B (zh) * 2022-05-31 2024-08-13 武汉真福医药股份有限公司 一种单克隆抗体qkma-1g41及其应用
CN115304677B (zh) * 2022-06-19 2024-08-16 湖北真福医药有限公司 一种抗枯草芽孢杆菌纤溶酶的单克隆抗体qkma-9a10及应用

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2426005T3 (es) 2004-07-23 2013-10-18 Acceleron Pharma Inc. Polipéptidos del receptor ACTRII, procedimientos y composiciones
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
EP3811965A1 (en) 2005-11-23 2021-04-28 Acceleron Pharma, Inc. Activin-actriia antagonists in use for promoting bone growth
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
EP2599495A1 (en) 2007-02-01 2013-06-05 Acceleron Pharma, Inc. Activin-ActRIIa Antagonists and Uses for Treating or Preventing Breast Cancer
TW201940502A (zh) 2007-02-02 2019-10-16 美商艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
KR20200054317A (ko) 2007-02-09 2020-05-19 악셀레론 파마 인코포레이티드 액티빈-ＡｃｔＲⅡＡ 길항제 및 암 환자에서 골 생장을 촉진시키기 위한 이의 용도
CA2699936A1 (en) 2007-09-18 2009-03-26 Acceleron Pharma Inc. Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion
HUE051137T2 (hu) 2008-08-14 2021-03-01 Acceleron Pharma Inc GDF-csapdák
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
WO2011063127A1 (en) 2009-11-18 2011-05-26 University Of Medicine And Dentistry Of New Jersey Targeting tumor cells with chemotherapeutic agents conjugated to matriptase antibodies
WO2010083034A1 (en) 2009-01-13 2010-07-22 Acceleron Pharma Inc. Methods for increasing adiponectin
US8178488B2 (en) 2009-06-08 2012-05-15 Acceleron Pharma, Inc. Methods for increasing thermogenic adipocytes
EP2440577A4 (en) 2009-06-12 2013-01-23 Acceleron Pharma Inc SHORTEN ACTRIIB FC FUSION PROTEINS
EP2470568A2 (en) 2009-08-29 2012-07-04 Abbott Laboratories Therapeutic dll4 binding proteins
US8710016B2 (en) 2009-11-17 2014-04-29 Acceleron Pharma, Inc. ActRIIB proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
US9849192B2 (en) 2009-11-18 2017-12-26 Rutgers, The State University Of New Jersey Targeting tumor cells with chemotherapeutic agents conjugated to matriptase antibodies
CN102770456B (zh) * 2009-12-04 2018-04-06 弗·哈夫曼-拉罗切有限公司 多特异性抗体、抗体类似物、组合物和方法
WO2011075636A2 (en) 2009-12-18 2011-06-23 Amgen Inc. Wise binding agents and epitopes
EP3072904A1 (en) 2010-03-02 2016-09-28 Abbvie Inc. Therapeutic dll4 binding proteins
CN103298832A (zh) 2010-11-08 2013-09-11 阿塞勒隆制药公司 Actriia结合剂及其用途
CA2857645A1 (en) 2011-11-30 2013-06-06 Wellstat Diagnostics, Llc Assays, antibodies, immunogens and compositions related to 5-fu
TW201333040A (zh) * 2012-01-06 2013-08-16 Bioalliance Cv 抗－輸鐵蛋白受器之抗體及其使用方法
FR2987293B1 (fr) * 2012-02-27 2014-03-07 Michelin & Cie Procede et appareil pour realiser des objets tridimensionnels a proprietes ameliorees
WO2014055663A1 (en) * 2012-10-02 2014-04-10 Rutgers, The State University Of New Jersey Specific delivery of toxins conjugated wtih antibodies to activated matriptase
US10195249B2 (en) 2012-11-02 2019-02-05 Celgene Corporation Activin-ActRII antagonists and uses for treating bone and other disorders
KR102149206B1 (ko) 2012-11-08 2020-08-31 세센 바이오, 아이엔씨. 인터루킨-6의 길항제 및 이의 용도
US20140171356A1 (en) * 2012-12-12 2014-06-19 The Board Of Trustees Of The Leland Stanford Junior University Chemically immobilized wnt protein and methods of use
KR20160067846A (ko) * 2013-09-05 2016-06-14 듀크 유니버시티 Nav1.7 항체 및 그의 사용 방법
US10035847B2 (en) 2013-10-02 2018-07-31 The Rockefeller University Amyloid protofibril antibodies and methods of use thereof
CN107135646B (zh) 2014-06-13 2022-03-15 阿塞勒隆制药公司 用于治疗溃疡的方法和组合物
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
EP4268843B1 (en) 2014-11-07 2025-09-03 F. Hoffmann-La Roche Ltd Improved il-6 antibodies
JP2018501307A (ja) 2014-12-03 2018-01-18 セルジーン コーポレイション アクチビン−ＡｃｔＲＩＩアンタゴニスト及び貧血を治療するための使用
AR107708A1 (es) 2016-02-23 2018-05-23 Eleven Biotherapeutics Inc Formulaciones de antagonista de il-6 y sus usos
IL261757B2 (en) 2016-03-18 2023-09-01 Univ Rutgers Treatment of stem cells with chemotherapeutic agents conjugated to anti-matriptase antibodies using connecting parts that can be broken down in the living body
US20190224339A1 (en) * 2016-04-29 2019-07-25 Voyager Therapeutics, Inc. Compositions for the treatment of disease
WO2018129248A1 (en) * 2017-01-06 2018-07-12 The Regents Of The University Of California Therapeutic anti-ige antibodies and methods and compositions thereof
KR20200045520A (ko) 2017-09-07 2020-05-04 오거스타 유니버시티 리서치 인스티튜트, 인크. 프로그래밍된 세포사 단백질 1에 대한 항체
CN118984837A (zh) 2022-01-28 2024-11-19 乔治穆内公司 作为pd-1激动剂的程序性细胞死亡蛋白1的抗体

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996039486A1 (en) * 1995-06-05 1996-12-12 Human Genome Sciences, Inc. Human ccn-like growth factor
AU2001271973A1 (en) * 2000-07-20 2002-02-05 Kevin P. Baker Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
WO2003106657A2 (en) * 2002-06-14 2003-12-24 Stowers Institute For Medical Research Wise/sost nucleic acid sequences and amino acid sequences
US20060002929A1 (en) * 2004-03-23 2006-01-05 Khare Sanjay D Monoclonal antibodies
FI3345607T3 (fi) * 2006-12-29 2022-11-30 Menetelmiä luun kasvun muuttamiseksi antamalla SOST- tai WISE-antagonistia tai antagonistia
EP2535354B1 (en) * 2007-06-18 2017-01-11 Merck Sharp & Dohme B.V. Antibodies to human programmed death receptor pd-1
JO3382B1 (ar) * 2008-12-23 2019-03-13 Amgen Inc أجسام مضادة ترتبط مع مستقبل cgrp بشري
SA110310369B1 (ar) * 2009-05-12 2014-09-02 Pfizer أجسام مضادة تخص dkk-1 واستخداماتها

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114364694A (zh) * 2019-07-12 2022-04-15 国立大学法人京都大学 靶向usag-1分子的用于牙齿再生治疗的中和抗体
CN114364694B (zh) * 2019-07-12 2024-05-10 国立大学法人京都大学 靶向usag-1分子的用于牙齿再生治疗的中和抗体
CN112180099A (zh) * 2020-09-15 2021-01-05 江南大学附属医院 子宫内膜异位症血清标志物的应用
CN115322258B (zh) * 2022-05-31 2024-08-13 武汉真福医药股份有限公司 一种单克隆抗体qkma-1g41及其应用
CN115304677B (zh) * 2022-06-19 2024-08-16 湖北真福医药有限公司 一种抗枯草芽孢杆菌纤溶酶的单克隆抗体qkma-9a10及应用
CN116712533A (zh) * 2023-07-03 2023-09-08 广东暨安特博生物科技有限公司 一种sostdc1蛋白在制备治疗皮肤病产品中的应用
CN116712533B (zh) * 2023-07-03 2024-02-02 广东暨安特博生物科技有限公司 一种sostdc1蛋白在制备治疗皮肤病产品中的应用

Also Published As

Publication number Publication date
EP2220118A2 (en) 2010-08-25
WO2009070243A2 (en) 2009-06-04
JP2011504501A (ja) 2011-02-10
CO6311002A2 (es) 2011-08-22
MX2010005656A (es) 2010-11-12
US8309092B2 (en) 2012-11-13
CA2705879A1 (en) 2009-06-04
US8043620B2 (en) 2011-10-25
IL205569A0 (en) 2010-12-30
WO2009070243A3 (en) 2009-10-29
TN2010000213A1 (en) 2011-11-11
MA31918B1 (fr) 2010-12-01
AU2008330125B2 (en) 2012-11-22
BRPI0820387A2 (pt) 2015-05-26
US20120003237A1 (en) 2012-01-05
JP5583591B2 (ja) 2014-09-03
EA201000844A1 (ru) 2011-10-31
KR20100099193A (ko) 2010-09-10
ZA201003578B (en) 2011-04-28
AU2008330125A1 (en) 2009-06-04
CR11523A (es) 2010-12-16
US20090130114A1 (en) 2009-05-21
JP2014167002A (ja) 2014-09-11

Similar Documents

Publication Publication Date Title
JP5583591B2 (ja) Ｗｉｓｅ結合抗体及びエピトープ
US11542325B2 (en) Anti-activin A antibodies and uses thereof
US20120288507A1 (en) Wise binding agents and epitopes
JP2023065375A (ja) 胸腺間質性リンパ球性新生因子に結合することができる抗原結合タンパク質
TWI494320B (zh) 結合劑
JP6121903B2 (ja) 抗ｎｇｆ抗体およびその使用
US20130203968A1 (en) Antibody-based diagnostics and therapeutics
US20190330321A1 (en) Antagonist antibodies that bind to human tgfb1, tgfb2 and to tgfb3 and their use for the treatment of lung fibrosis
JP2010502740A5 (enExample)

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20101222